AMARIN®

Second Quarter 2022 Financial Results and Business Update Conference Call



Karim Mikhail
President & CEO

Dr. Steve Ketchum
President of R&D and CSO

Tom Reilly
CFO

August 3, 2022

Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic product launch, intellectual property, cash flow, research and development, and other statements that are forward-looking in nature and depend upon or refer to future events or conditions, including financial guidance and milestones.

These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.

Karim Mikhail
President & CEO

SECOND QUARTER
2022 HIGHLIGHTS

Amarin Growth Strategy

AMARIN

Received a published positive reimbursement decision from NICE for VAZKEPA® in **England & Wales**

In parallel, Amarin continues to progress well with its reimbursement discussions in the other European markets and remains on track to receive pricing decisions in up to eight countries with plans to launch VAZKEPA in up to six European countries this year.

Note: FX conversion current as of August 2, 2022.

First Health Technology Assessment (HTA) reimbursement in an "EU5" country marking a significant milestone for Amarin's

EUROPEAN GROWTH STRATEGY

UK's National Institute for Health and Care Excellence (NICE) issued its draft Final Appraisal Document (FAD)

RECOMMENDING THE USE OF VAZKEPA® (ICOSAPENT ETHYL) IN ENGLAND AND WALES

Priced at

£144.21 PER 120 SOFT CAPSULES

(i.e. 30-day supply; equivalent of approximately 172 EUR or 176 USD*)

Reimbursed to

REDUCE THE RISK OF CARDIOVASCULAR (CV) EVENTS

in adult statin-treated patients at high cardiovascular risk who have elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]), LDL-C levels >1.04 mmol/L and ≤ 2.60 mmol/L, and established cardiovascular disease (eCVD),

AMARIN

Significant Market Opportunity

4M deaths per year in Europe WHO region due to CVD[1]

~€210B annual CVD costs to European Union[2]

10+ years of market exclusivity in Europe

1. ESC: Cardiovascular Disease Statistics 2019
2. European Heart Network. European Cardiovascular Disease Statistics 2017. https://ehnheart.org/cvd-statistics/cvd-statistics-2017.html. Accessed January 2022

AMARIN

Europe Progress To Date in 2022:

- ✓ Achieved national reimbursements in Sweden, England & Wales and have achieved individual reimbursement in Denmark.
- ✓ Also making progress in additional key European markets:
  - **Spain:** Price negotiations begun Ministry of Health, possible pricing and reimbursement decision before the end of 2022.
  - **Germany:** On the market with temporary reimbursement; remain in discussions with German health authorities and are actively evaluating our presence in Germany based on ongoing negotiations.
  - **France:** Received positive reimbursement assessment from HAS; price negotiations continue to progress.
  - **Portugal, Austria, Switzerland:** New dossiers submitted and are now in pricing and reimbursement negotiations.

Progress on European Product Commercialization

AMARIN

*Secured individual reimbursement; full reimbursement submission in process
**Initial filing denied; refiling reimbursement submission
***Initial G-BA finding no benefit; reimbursement discussions ongoing
****Scientific Evidence Assessment/Recommendation ongoing; Reimbursement Price Negotiations initiated in parallel

Total Revenue by Quarter



Second Quarter 2022 Results

- Second quarter 2022 total net revenue was **$94.4 MILLION,** including U.S. product revenue of **$90.6 MILLION.**
- U.S. net revenues continued to be impacted by a third generic entrant to the market, resulting in lower volume and lower average net selling price.
- Importantly, the second quarter was the first full quarter where three generic entrants were in the market versus one generic entrant in the prior year period.
- Amarin saw a normalization of the trade destocking experienced in the first quarter of 2022. Exclusive business has stabilized.
- Amarin is offsetting market dynamics with cost containment efforts; announced cost reduction plan in June to reduce operating costs by approximately **$100 MILLION OVER THE NEXT 12 MONTHS**
- Amarin continues to actively monitor key performance indicators in the U.S. market to support our steps forward.

AMARIN

International Growth Expansion Through Partnerships Represents Potential $1B Opportunity

Plans to Bring Unique Cardioprotective Benefits of VASCEPA/VAZKEPA to 20 Additional Markets

1ST WAVE 2022
UP TO

6

COUNTRIES

2ND WAVE 2023
UP TO

9

COUNTRIES

3RD WAVE 2024
UP TO

5

COUNTRIES

Supported by REDUCE-IT Study and U.S. FDA and EMA Filings

AMARIN

Note: The company is pursuing expansion into these various additional markets and the status of regulatory and/or patent approval will vary between market to market.

Dr. Steve Ketchum
President of R&D and CSO

SECOND QUARTER
R&D HIGHLIGHTS

Addressing Recent Comments on REDUCE-IT and Post Hoc Exploratory Biomarker Analyses

Exploratory biomarker analyses were not conducted to demonstrate effectiveness in reducing CV risk; conducted to preliminarily explore subset of potential pathways via which IPE might exert some level of effect in REDUCE-IT.

***Circulation* paper highlights relative percentage increases rather than the absolute increases across the set of biomarkers studied in this analysis.** When analyzing results from an absolute increase perspective, they are small and do not correlate to any meaningful changes in outcomes seen in the REDUCE-IT trial.

These biomarkers are exploratory and none have been sufficiently validated or correlated with CVD risk in and across clinical trials to enable them to be relied upon to draw meaningful conclusions.

***Circulation* paper authors submitted a number of additional analyses as part of the manuscript review process which were not included in the published paper.** These analyses provide a more balanced perspective on the biomarker data.



Circulation

JOURNAL OF THE AMERICAN HEART ASSOCIATION

Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Paul M. Ridker, Nader Rifai, Jean MacFadyen, Robert J. Glynn, Lixia Jiao, Ph. Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Jean-Claude Tardif, Christie M. Ballantyne, R. Preston Mason and Deepak L. Bhatt

Originally published 28 Jun 2022 Circulation. 2022;0:10.1161/CIRCULATIONAHA.122.059410

REDUCE-IT Sub-Population Data To Be Presented at ESC 2022

ESC will feature data in specific patient sub-populations at **increased risk of a cardiovascular (CV) event** from the landmark **REDUCE-IT** cardiovascular outcomes trial

LATE-BREAKING SCIENCE PRESENTATION

Session: Latest science in primary and secondary prevention and environmental health

"SIGNIFICANT REDUCTION IN ST-ELEVATION MI WITH ICOSAPENT ETHYL IN REDUCE-IT"

Deepak L. Bhatt, Robert P. Giugliano, Ph. Gabriel Steg, Michael Miller, et al.

Available On-Demand from August 26 at 2:18 p.m. CEST (8:18 a.m. EST)

ORAL PRESENTATION

Session: Optimal risk factor therapy in high-risk patients

"ICOSAPENT ETHYL DIMINISHES CVD RISK IN SMOKERS: REDUCE-IT SMOKING"

Michael Miller, Deepak L. Bhatt, Ph. Gabriel Steg, Eliot A. Brinton , et al.

Available On-Demand from August 28 at 11:50 a.m. CEST (5:50 a.m. EST)



Development of a Fixed-Dose Combination Portfolio

IMPROVE ADHERENCE

INCREASED ADHERENCE
as evidenced by studies performed both in Europe and the US, as well as
ADEQUATE DOSING
of fixed-dose combination treatment immediately after a CVD event has the
POTENTIAL TO IMPROVE CLINICAL OUTCOMES[1]

GREATER PATIENT CONVENIENCE

Reduced pill burden, meaning
GREATER CONVENIENCE
for high-risk cardiovascular patients that have other comorbidities and, therefore, multiple medications, needing repeat visits to HCP for treatment intensification

COMMERCIAL OPPORTUNITY

Allows us to maximize the
INVESTMENT
made into the REDUCE-IT study, where IPE was used on top of a statin, by offering the benefits of VASCEPA/VAZKEPA in a
BROAD PORTFOLIO OF PRODUCTS

If successful, the FDC product would carry the most significant cardiovascular risk outcome benefit label and potentially additional protection for patients.

AMARIN

1. Drexel H, Coats AJS, Spoletini I, et al. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. *Eur Heart J Cardiovasc Pharmacother*. 2020;6(2):115-121.

Tom Reilly
CFO

SECOND QUARTER
FINANCIAL RESULTS

Q2 2022 Financial Highlights

	Q1 2022	Q2 2022	Q2 2021
Total Net Revenue	$94.6 million	$94.4 million	$154.5 million
Cost of Goods Sold*		$50.8 million	$32.2 million
Gross Margin (Overall)**		72%	79%
Operating Expenses***		$106.5 million	$113.6 million
SG&A Expenses		$86.9 million	$107.2 million
R&D Expenses		$9.4 million	$6.4 million

	Q2 2022
GAAP Net Loss	$70.0 million
Basic and Diluted Loss Per Share	$0.18

	June 30, 2022
Aggregate Cash & Investments	$324.6 million

***Q2 2022 Cost of Goods Sold includes $15 million in restructuring inventory**
****Q2 2022 Gross Margin excludes $15 million in restructuring and $9.6 million of unsellable inventory, reportable Gross Margin was 46%**
*****Q2 2022 Operating Expenses include $10.2 million related to restructuring**

AMARIN



Leading a new paradigm
in preventive cardiovascular
care and growing our impact
for patients globally

AMBITIONS for AMARIN

AMARIN

Vascepa® (icosapent ethyl)

Vazkepa® (icosapent ethyl)



Investor Presentation

May 2022